The Unapproved Fixed-Dose Combination Drugs in India: A Public Health Concern

By Staff Writer

November 25, 2023

The Ongoing Issue of Unapproved Fixed-Dose Combination Drugs in India

The regulation of medicines in India, a responsibility shared between the central government and individual states, has been a source of friction and calls for reform. One area of notable concern has been the regulation of Fixed-Dose Combination drugs (FDCs), specifically antibiotic FDCs. Despite regulatory initiatives since 2007, hundreds of unapproved antibiotic FDC formulations remained on the Indian market, Accounting for over 700 million of the 4.5 billion standard units sold in 2020. This issue extends beyond India’s borders, contributing to the global concern of increasing antimicrobial resistance.

The Impact on Public Health and Global Concerns

India’s vast sales of centrally unapproved FDCs pose a significant public health concern. This concern escalates when considering the context of increasing antimicrobial resistance. In 2020, 41.5% of the 4.5 billion standard units of antibiotic FDCs sold were attributed to combinations listed as ‘not recommended’ by WHO. The limited progress in controlling these FDCs is a result of weak, convoluted, and inefficient regulatory enforcement.

Recommendations and Further Steps

Regular surveillance of the market, informed regulatory enforcement, and antimicrobial stewardship are recommended. Criminal proceedings should be considered against manufacturers of the formulations marketed without a record of prior Central Drugs Standard Control Organisation (CDSCO) approval. The prescription of only well-evidenced FDCs, such as those listed in National List of Essential Medicines (NLEM), would reduce the use of FDCs and facilitate antimicrobial stewardship. Further research is needed on the control measures and trends in sales of FDCs in other therapeutic areas.

Reference url

Recent Posts

DTC telehealth partnerships
           

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
       

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
           

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.